Drug Trial Radar · NCT05647811
Study of NM8074 in Adult C3 Glomerulopathy Patients
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
May 2027
Primary completion
Aug 2029
Study completion Jul 2030
Sponsor
- Lead sponsor
- NovelMed TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib, open-label, dose-escalation study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to patients with C3 Glomerulopathy.
Conditions
- C3 Glomerulopathy
Interventions
NM8074Drug
NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Monitoring for incidence of Adverse Events (AEs)/Serious Adverse Events (SAEs)Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3
- Change from Baseline or Percent Change from Baseline in Urine Protein to Creatine Concentration Ratio (UPCR)Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3
- Change from Baseline or Percent Change from Baseline in Urine Albumin to Creatinine Concentration Ratio (UACR)Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3
- Ratio to Baseline of UPCR and UACRTime frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3
- Change from Baseline or Percent Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.